APA (7th ed.) Citation

TY, L., PC, T., SW, L., & ML, Y. (2026). Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study". Clinical and molecular hepatology, 32(1), e68. https://doi.org/10.3350/cmh.2025.0235

Chicago Style (17th ed.) Citation

TY, Lee, Tsai PC, Lee SW, and Yu ML. "Emerging Evidence Supports Direct-acting Antiviral Therapy for HCC Patients Beyond the Early Stage: Correspondence to Editorial on "Direct-acting Antiviral Therapy for Patients with HCV-related Hepatocellular Carcinoma: A Nationwide Cohort Study"." Clinical and Molecular Hepatology 32, no. 1 (2026): e68. https://doi.org/10.3350/cmh.2025.0235.

MLA (9th ed.) Citation

TY, Lee, et al. "Emerging Evidence Supports Direct-acting Antiviral Therapy for HCC Patients Beyond the Early Stage: Correspondence to Editorial on "Direct-acting Antiviral Therapy for Patients with HCV-related Hepatocellular Carcinoma: A Nationwide Cohort Study"." Clinical and Molecular Hepatology, vol. 32, no. 1, 2026, p. e68, https://doi.org/10.3350/cmh.2025.0235.